OR WAIT 15 SECS
The National Comprehensive Cancer Network (NCCN) Antiemesis panel recently updated its guidelines for the prevention of CINV to include palonosetron (Aloxi, MGI Pharma/Helsinn Healthcare) injection in multiagent antiemetic regimens for use with highly and moderately chemotherapy. The updated guidelines also include aprepitant (Emend, Merck) in multiagent antiemetic regimens for use with highly and moderately emetogenic chemotherapy. The guidelines update was announced at the NCCN 9th Annual Clinical Practice Guidelines and Outcomes Data in Oncology Conference, held in March in Hollywood, Fla.
Related Content:Treatment Areas